Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer
复制标题
DOI：
10.1016/j.breast.2018.08.096
复制
发表时间：
2018-12-01
期刊：
影响因子：
3.9
通讯作者：
Livi, Lorenzo
中科院分区：
文献类型：
--
作者：
Meattini, Icro;Desideri, Isacco;Livi, Lorenzo
Ribociclib是一种CDK4-6抑制剂，最近被美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）批准作为转移性乳腺癌（MBC）的一线治疗药物。关键试验显示，与单独内分泌治疗相比，无进展生存期有显著改善。然而，与单独的内分泌治疗相比，具有挑战性的毒性，当与姑息疗法联合放疗（RT）时，安全性可能是一个问题。目前还没有关于核素西尼和姑息性放疗联合使用的公开数据。我们报告了在佛罗伦萨大学（Florence, Italy）放射肿瘤学部门接受姑息性放疗同时使用核素西尼和来曲唑作为MBC一线治疗的前5名患者的初步经验。(C) 2018 Elsevier Ltd.版权所有。
Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone. However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach.There are no available published data regarding the combination of ribociclib and palliative RT. We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC. (C) 2018 Elsevier Ltd. All rights reserved.